Majkowska L, Mamos E, Fuchs H, Pynka S, Jastrzebska M, Krzyzanowska B, Czekalski S
Klinika Endokrynologii i Chorób Przemiany Materii PAM, Szezecin.
Pol Arch Med Wewn. 1994 Aug;92(2):147-53.
The aim of the study was to evaluate plasma concentration of fibrinogen, plasma activity of antithrombin III (AT-III) and plasma activity of plasminogen activator inhibitor (PAI-I) in insulin-dependent diabetic (IDDM) patients and the assessment of correlation between them and the parameters of glyco-metabolic control comprising glycemia and concentrations of fructosamine and glycated hemoglobin HbA1c. Eighteen IDDM patients (mean age 28.3 +/- 11.3 ys, mean duration of disease 12.2 +/- 5.3 ys) without over nephropathy and without macroangiopathy were investigated. Control group consisted of 8 healthy subjects. Plasma fibrinogen concentrations were similar in IDDM patients and in controls (3.54 +/- 0.45 g/l and 3.31 +/- 0.54 g/l respectively). Plasma activity of AT-III in diabetic patients (90.6 +/- 22.4%) was similar to that in healthy subjects (94.6 +/- 25.0%). Fibrinogen concentrations and AT-III activities showed no correlation with glycemia and concentrations of fructosamine and HbA1c. Plasma activity of PAI-I was significantly lower in diabetics than in controls (respectively 1.56 +/- 0.72 U/ml and 2.75 +/- 1.25 U/ml, p < 0.005). PAI-I activity correlated negatively with fasting blood glucose (p < 0.05) but did not correlate with concentrations of fructosamine or HbA1c. The results suggest that glycemic control in diabetic patients do not influence on concentrations of fibrinogen and activity of AT-III but diminished activity of PAI-I is related to hyperglycemia.
本研究旨在评估胰岛素依赖型糖尿病(IDDM)患者的血浆纤维蛋白原浓度、抗凝血酶III(AT-III)的血浆活性以及纤溶酶原激活物抑制剂(PAI-I)的血浆活性,并评估它们与包括血糖、果糖胺浓度和糖化血红蛋白HbA1c在内的糖代谢控制参数之间的相关性。对18例无肾病和大血管病变的IDDM患者(平均年龄28.3±11.3岁,平均病程12.2±5.3年)进行了研究。对照组由8名健康受试者组成。IDDM患者和对照组的血浆纤维蛋白原浓度相似(分别为3.54±0.45 g/l和3.31±0.54 g/l)。糖尿病患者的AT-III血浆活性(90.6±22.4%)与健康受试者相似(94.6±25.0%)。纤维蛋白原浓度和AT-III活性与血糖、果糖胺浓度和HbA1c均无相关性。糖尿病患者的PAI-I血浆活性显著低于对照组(分别为1.56±0.72 U/ml和2.75±1.25 U/ml,p<0.005)。PAI-I活性与空腹血糖呈负相关(p<0.05),但与果糖胺或HbA1c浓度无关。结果表明,糖尿病患者的血糖控制对纤维蛋白原浓度和AT-III活性无影响,但PAI-I活性降低与高血糖有关。